FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND
by Press Release from Outbreak News Today on (#522N6)
CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has received a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) to investigate the use of CM4620-IE in patients with severe COVID-19 pneumonia who are at risk ["]
The post FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND appeared first on Outbreak News Today.